US hospital data show 30-day mortality rates for candidemia rose from 25% in 2015 to 32% in 2024.
Analysis of C auris clinical isolates by the CDC's Antimicrobial Resistance Laboratory Network finds that 95% were resistant to fluconazole and 15% to amphotericin B.
A case-control study finds multiple comorbidities, invasive devices, and low functional status are significantly associated with progression from colonization to clinical symptoms.
Data from a new survey show Candida auris, which can cause deadly invasive infections, is spreading rapidly in European hospitals.
Patients infected with the multidrug-resistant fungus were "characterized by significant underlying morbidity and disease burden," the study authors write.
The higher death rate was likely driven by strained healthcare systems amid the pandemic and more patients susceptible to Candida species because of severe COVID-19, the researchers say.
Hospital researchers say the observed increase in clinical cases of the multidrug-resistant fungus mirrors national trends.
Expanded screening criteria helped a New York City hospital identify more patients who were colonized with the multidrug-resistant fungus.
Incidence of C auris infection and colonization tripled at Mount Sinai Hospital from 2019 through 2022.
Only 37% of infectious diseases practitioners said their facility screens patients for the drug-resistant fungus.
